lisocabtagene maraleucel (Breyanzi) Report issue

Cell therapy Orphan Drug FDA Approved FDA Breakthrough Therapy FDA

Active Ingredient History

NOW
  • Now
Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Lymphoma, Follicular (approved 2021)

Lymphoma, Large B-Cell, Diffuse (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Immune System Diseases (Phase 2)

Immunoproliferative Disorders (Phase 2)

Lymphatic Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Neoplasms by Histologic Type (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue